Deep learning based digital pathology for predicting treatment response to first-line PD-1 blockade in advanced gastric cancer

Yifan Liu,Wei Chen,Ruiwen Ruan,Zhimei Zhang,Zhixiong Wang,Tianpei Guan,Qi Lin,Wei Tang,Jun Deng,Zhao Wang,Guanghua Li
DOI: https://doi.org/10.1186/s12967-024-05262-z
IF: 8.44
2024-05-11
Journal of Translational Medicine
Abstract:Advanced unresectable gastric cancer (GC) patients were previously treated with chemotherapy alone as the first-line therapy. However, with the Food and Drug Administration's (FDA) 2022 approval of programmed cell death protein 1 (PD-1) inhibitor combined with chemotherapy as the first-li ne treatment for advanced unresectable GC, patients have significantly benefited. However, the significant costs and potential adverse effects necessitate precise patient selection. In recent years, the advent of deep learning (DL) has revolutionized the medical field, particularly in predicting tumor treatment responses. Our study utilizes DL to analyze pathological images, aiming to predict first-line PD-1 combined chemotherapy response for advanced-stage GC.
medicine, research & experimental
What problem does this paper attempt to address?
The problem that this paper attempts to solve is how to use deep - learning technology to analyze pathological images in patients with advanced gastric cancer and predict patients' response to first - line PD - 1 inhibitor - combined chemotherapy. Specifically, the research aims to develop a deep - learning model based on digital pathology images to identify which patients may have a good response to this treatment regimen, thereby achieving personalized treatment planning and improving the clinical application efficiency of immunotherapy. ### Research Background - **Treatment status of advanced gastric cancer**: Patients with advanced gastric cancer (GC) are usually at an inoperable stage at the time of diagnosis. Traditional first - line treatment is mainly systemic chemotherapy, but the efficacy is limited, and the median survival period is about 12 months. - **Progress in immunotherapy**: In recent years, PD - 1 inhibitor - combined chemotherapy has been approved as a first - line treatment regimen for advanced gastric cancer, significantly improving patients' survival rates. However, high costs and potential adverse reactions require precise selection of beneficiary patients. - **Application of deep learning**: The application of deep - learning technology in medical image analysis is becoming more and more widespread, especially showing great potential in predicting tumor treatment responses. ### Research Methods - **Data collection**: 313 H&E - stained sections from 264 patients with advanced gastric cancer were collected from four medical centers. - **Model construction**: An ensemble model was constructed using three deep - learning models (DenseNet121, EfficientNet - B4, Swin Transformer V2) to generate an immune checkpoint inhibitor response score (ICIsRS). - **Performance evaluation**: The predictive performance of the model was evaluated through internal test sets and external validation sets. The main indicators include accuracy (ACC), sensitivity (SENS), specificity (SPEC), positive predictive value (PPV), negative predictive value (NPV) and F1 - score. ### Main Results - **Model performance**: The ensemble model showed excellent predictive performance on multiple test sets, with AUC values of 0.92, 0.95, 0.96 and 1.00 respectively. - **Statistical differences in ICIsRS**: Through box - plot analysis, it was found that there were significant differences in ICIsRS between the "good response" group and the "adverse response" group (all p - values ≤ 0.001). - **Visual analysis**: Through heat - map visualization, it was found that poor differentiation or more diffuse tumor tissue characteristics (such as signet - ring cells or floating cells in mucus) and decreased lymphocyte infiltration were associated with weaker immunotherapy responses; conversely, patients whose tumor cells were closer to normal tissues and had increased lymphocyte infiltration had better responses to immunotherapy. ### Conclusions - **Innovation points**: This is the first attempt to use pre - treated biopsy samples to predict the sensitivity of patients with advanced gastric cancer to first - line PD - 1 inhibitor - combined chemotherapy. - **Clinical significance**: As a new digital - pathological biomarker, ICIsRS can effectively predict the treatment responses of patients with advanced gastric cancer, providing a new tool for personalized treatment and helping to improve the clinical application effects of immunotherapy. Through these research results, the authors hope to provide clinicians with a reliable tool to more accurately select patients suitable for receiving PD - 1 inhibitor - combined chemotherapy, thereby improving treatment effects and reducing unnecessary side effects.